Acadia Pharma (ACAD) Tops Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Acadia Pharma (ACAD) Tops Q4 EPS by 5c

ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

February 26, 2019 4:05 PM EST

- Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17

- Full Year 2018 Net Sales Grew to $223.8 Million, a 79% Increase Over Full Year 2017

- Late Stage Pipeline Progressing with Five Clinical Programs Ongoing or Commencing in 2019

- 2019 Guidance: Net Sales $275 Million to $300 Million

SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,... More